Identification
- Brand Names
- Nasopen PE, Poly Hist Pd
- Generic Name
- Thonzylamine
- DrugBank Accession Number
- DB11235
- Background
Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with Clofedanol or Phenylephrine for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Thonzylamine (DB11235)
- Weight
- Average: 286.379
Monoisotopic: 286.179361344 - Chemical Formula
- C16H22N4O
- Synonyms
- neohetramine
- Thonzylamine
Pharmacology
- Indication
Thozylamine is indicated for use in the symptomatic control of allergic rhinitis or other upper respiratory allergic symptoms Label. It is typically a part of combination over the counter products.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Allergies Combination Product in combination with: Phenylephrine (DB00388) ••• ••• •••••• Used in combination to treat Allergies Combination Product in combination with: Dextromethorphan (DB00514), Phenylephrine (DB00388) ••• ••• •••••• Used in combination to treat Allergies Combination Product in combination with: Naphazoline (DB06711) •••••••••••• •••••••• • ••••• Used in combination to treat Coughing Combination Product in combination with: Phenylephrine (DB00388), Dextromethorphan (DB00514) ••• ••• •••••• Used in combination to treat Coughing Combination Product in combination with: Clofedanol (DB04837) ••• ••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Thonzylamine is a first-generation antihistamine. It antagonizes the action of histamine to relief allergic symptoms like nasal congestion, runny nose, itchy eyes, itchy nose and throat, and sneezing Label,1
- Mechanism of action
Thonzylamine competes with histamine for binding to the H1 histamine receptor 1. Binding of histamine to this receptor stimulates vasodilation and increased vascular permeability leading to nasal congestion and runny nose 3. Histamine also produces itchiness by stimulating nerve endings which can result in sneezing. By blocking these effects, thonzylamine can reduce or eliminate symptoms of allergic rhinitis.
Target Actions Organism AHistamine H1 receptor antagonistHumans UMuscarinic acetylcholine receptor M1 antagonistHumans UMuscarinic acetylcholine receptor M2 antagonistHumans UMuscarinic acetylcholine receptor M3 antagonistHumans UMuscarinic acetylcholine receptor M4 antagonistHumans UMuscarinic acetylcholine receptor M5 antagonistHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Doses of up to 300 mg/day for up to 4 days have produces no observable toxic effects in humans 2. In a chronic toxicity study, rats were given up to 200 mg/kg/day orally for 91 days with no observable toxic effects 1.
- Pathways
Pathway Category Thonzylamine H1-Antihistamine Action Drug action - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAclidinium The risk or severity of adverse effects can be increased when Thonzylamine is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Thonzylamine. Alfentanil The risk or severity of adverse effects can be increased when Thonzylamine is combined with Alfentanil. Alloin The therapeutic efficacy of Alloin can be decreased when used in combination with Thonzylamine. Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Thonzylamine. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Thonzylamine hydrochloride 6K9YKD48Y4 63-56-9 HRYJPHOTGFERGT-UHFFFAOYSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image IRIDINA ANTISTAMINICO Thonzylamine hydrochloride (1 mg/ml) + Naphazoline nitrate (0.8 MG/ML) Solution / drops Ophthalmic Montefarmaco Otc S.P.A. 2014-07-08 2023-11-07 Italy 
Nasopen PE Thonzylamine hydrochloride (50 mg/15mL) + Phenylephrine hydrochloride (10 mg/15mL) Liquid Oral GM Pharmaceuticals, INC 2012-10-03 Not applicable US 
Poly Hist PD Thonzylamine hydrochloride (6.25 mg/1mL) + Chlophedianol hydrochloride (6.25 mg/1mL) Liquid Oral Poly Pharmaceuticals, Inc. 2013-07-01 Not applicable US Poly-Hist DM Thonzylamine hydrochloride (25 mg/5mL) + Dextromethorphan hydrobromide monohydrate (10 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL) Liquid Oral Poly Pharmaceuticals, Inc. 2013-06-22 Not applicable US TexaClear Kids Sinus Relief Thonzylamine hydrochloride (50 mg/30mL) + Phenylephrine hydrochloride (5 mg/30mL) Liquid Oral GM Pharmaceuticals, INC 2015-06-15 2019-01-16 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Poly-Hist DM Thonzylamine hydrochloride (25 mg/5mL) + Dextromethorphan hydrobromide monohydrate (10 mg/5mL) + Phenylephrine hydrochloride (5 mg/5mL) Liquid Oral Poly Pharmaceuticals, Inc. 2013-06-22 Not applicable US
Categories
- ATC Codes
- D04AA01 — Thonzylamine
- D04AA — Antihistamines for topical use
- D04A — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D04 — ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
- D — DERMATOLOGICALS
- R06AC — Substituted ethylene diamines
- R06A — ANTIHISTAMINES FOR SYSTEMIC USE
- R06 — ANTIHISTAMINES FOR SYSTEMIC USE
- R — RESPIRATORY SYSTEM
- Drug Categories
- Agents producing tachycardia
- Antiallergic Agents, Excl. Corticosteroids
- Anticholinergic Agents
- Antihistamines for Systemic Use
- Antihistamines for Topical Use
- Antipruritics, Incl. Antihistamines, Anesthetics, Etc.
- Dermatologicals
- Histamine Agents
- Histamine Antagonists
- Histamine H1 Antagonists
- Muscarinic Antagonists
- Nasal Preparations
- Neurotransmitter Agents
- Substituted Ethylene Diamines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol ethers
- Sub Class
- Anisoles
- Direct Parent
- Anisoles
- Alternative Parents
- Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Benzylamines / Aminopyrimidines and derivatives / Alkyl aryl ethers / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Alkyl aryl ether / Amine / Aminopyrimidine / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzylamine / Dialkylarylamine / Ether / Heteroaromatic compound show 13 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R79646H5Z8
- CAS number
- 91-85-0
- InChI Key
- GULNIHOSWFYMRN-UHFFFAOYSA-N
- InChI
- InChI=1S/C16H22N4O/c1-19(2)11-12-20(16-17-9-4-10-18-16)13-14-5-7-15(21-3)8-6-14/h4-10H,11-13H2,1-3H3
- IUPAC Name
- N-[2-(dimethylamino)ethyl]-N-[(4-methoxyphenyl)methyl]pyrimidin-2-amine
- SMILES
- COC1=CC=C(CN(CCN(C)C)C2=NC=CC=N2)C=C1
References
- General References
- SCUDI JV, REINHARD JF, DREYER NB: Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948 May;19(3):184-99. [Article]
- AARON TH, CRIEP LH: Neohetramine and thephorin; two new antihistaminic drugs. Can Med Assoc J. 1948 Nov;59(5):438-41. [Article]
- Chapter 39: Histamine, Bradykinin, and Their Antagonists. (2018). In Goodman & Gilman's: The Pharmacological Basis of Therapeutics (13th ed.). McGraw-Hill Education. [ISBN:978-1-25-958473-2]
- External Links
- Human Metabolome Database
- HMDB0240222
- PubChem Compound
- 5457
- PubChem Substance
- 347827947
- ChemSpider
- 5258
- 1360721
- ChEBI
- 104017
- ChEMBL
- CHEMBL1623738
- ZINC
- ZINC000000057513
- Wikipedia
- Thonzylamine
- FDA label
- Download (190 KB)
- MSDS
- Download (82.2 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution / drops Ophthalmic Solution / drops Ophthalmic Solution / drops Conjunctival Liquid Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 173-176 Scudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99. water solubility Highly Soluble Scudi JV, Reinhard JF, Dreyer NB. Pharmacologic characteristics of neohetramine, a new antihistaminic drug. J Allergy. 1948;19(3):184-99. - Predicted Properties
Property Value Source Water Solubility 0.733 mg/mL ALOGPS logP 2.4 ALOGPS logP 2.42 Chemaxon logS -2.6 ALOGPS pKa (Strongest Basic) 8.62 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 41.49 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 86.19 m3·mol-1 Chemaxon Polarizability 32.42 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 182.1746133 predictedDarkChem Lite v0.1.0 [M-H]- 170.85757 predictedDeepCCS 1.0 (2019) [M+H]+ 182.8170133 predictedDarkChem Lite v0.1.0 [M+H]+ 173.21556 predictedDeepCCS 1.0 (2019) [M+Na]+ 182.7976133 predictedDarkChem Lite v0.1.0 [M+Na]+ 179.3087 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Histamine receptor activity
- Specific Function
- In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
- Gene Name
- HRH1
- Uniprot ID
- P35367
- Uniprot Name
- Histamine H1 receptor
- Molecular Weight
- 55783.61 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- G-protein coupled acetylcholine receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM2
- Uniprot ID
- P08172
- Uniprot Name
- Muscarinic acetylcholine receptor M2
- Molecular Weight
- 51714.605 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Guanyl-nucleotide exchange factor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM4
- Uniprot ID
- P08173
- Uniprot Name
- Muscarinic acetylcholine receptor M4
- Molecular Weight
- 53048.65 Da
References
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- Curator comments
- Thonzylamine is known to have weak parasympatholytic activity. No binding studies have been performed.
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM5
- Uniprot ID
- P08912
- Uniprot Name
- Muscarinic acetylcholine receptor M5
- Molecular Weight
- 60073.205 Da
References
Drug created at December 03, 2015 16:51 / Updated at February 21, 2021 18:53